Insomnia Treatment Org 50081 moves to phase 3 clinical trials

Insomnia effects more than 70 million American a year, with the elderly and women being most impacted by this sleep disorder.

Lack of sleep on a continual basis can lead to illnesses such as depression.

The number of people seeking treatment for insomnia is expected to rise over the next few years.

Medication may be helpful for insomniacs, and one such compound: Org 50081, a serotonin 2 blocker, has just entered phase III clinical development.

This product showed positive results for helping patients fall asleep more quickly and to feel more rested when they woke up.

Org 50081 is unique for an insomnia drug, because it works on the serotonergic and histaminergic pathways rather than interacting with the GABA receptors.

For the layperson, this translates into better sleep without dependency on the drug.

Org 50081 is expected to be released, at first, to treat insomnia and the hot flashes associated with menopause.